![]() |
市場調查報告書
商品編碼
1800762
2025 年至 2033 年細胞分析市場報告(按產品、分析類型、技術、最終用戶和地區)Cell Analysis Market Report by Product, Analysis Type, Techniques, End-User, and Region 2025-2033 |
2024年,全球細胞分析市場規模達222億美元。展望未來, IMARC Group預計到2033年,該市場規模將達到412億美元,2025-2033年期間的複合年成長率(CAGR)為7.1%。個人化醫療的轉變、全球癌症病例的增加以及人工智慧和機器學習在細胞分析領域的日益融合,是推動市場成長的一些關鍵因素。
癌症負擔日益加重
全球癌症病例的不斷增加是推動市場成長的主要動力。癌症研究中的細胞分析工具和技術可以精確地表徵腫瘤細胞,包括其基因突變、蛋白質表現譜以及腫瘤微環境內的細胞交互作用。癌症患者數量的不斷成長正在催化細胞分析市場佔有率。例如,根據美國癌症協會 2022 年的最新消息,估計 2022 年美國將新增約 1,918,030 例癌症病例。此外,肺癌和乳癌是個人中最常見的兩種癌症。加拿大癌症協會 (CCS) 表示,2020 年,近 29,800 名加拿大人被診斷出患有肺癌,佔所有新癌症病例的 13%。預計約有 21,200 名加拿大人將死於肺癌,佔 2020 年所有癌症死亡人數的 25%。這表明對有效和更先進的癌細胞分析的需求日益成長。因此,對有效和持久的癌症治療的需求不斷增加,預計將為整個市場提供豐厚的成長機會。
新型分子的開發日益增多
各種傳染病的盛行率不斷上升,促使新型分子和疫苗的研發,進而增加了細胞分析市場的收入。細胞分析工具在藥物發現和開發中發揮至關重要的作用,使研究人員能夠評估潛在候選藥物的有效性、安全性和作用機制。此外,各種製藥和生物技術公司越來越依賴細胞分析技術和工具來推出新的和改良的藥物。例如,根據美國國會預算辦公室 2021 年發布的資料,全球製藥業在 2020 年的研發支出接近 2,000 億美元,而 2019 年為 8,300 萬美元。同樣,丹納赫公司在 2021 年的研發投資為 17.42 億美元,而 2020 年為 13.48 億美元。此外,Bio-Rad Laboratories Inc. 在 2021 年的投資為 8.796 億美元,而 2020 年為 8.003 億美元。因此,公司在研發方面不斷增加的投資進一步提高了公司採用創新細胞分析技術的能力,從而推動了細胞分析市場的成長。
策略合作與收購數量不斷增加
各大市場主要參與者正在建立合作夥伴關係,以開發新的和改進的細胞分析方法、工具和技術。例如,2022年8月,屢獲殊榮的CellDrop自動細胞計數器製造商DeNovix Inc.開發了兩款專用的細胞核計數應用程式,能夠區分分離的細胞核、完整的細胞與細胞碎片。 CellDrop系列是基於影像的自動細胞計數器系列。系統配備7吋高清觸控屏,可即時預覽和即時查看結果。同樣,索尼公司於2022年11月推出了SFA - 生命科學雲平台,這是一種流式細胞資料分析雲解決方案,可以利用流式細胞儀獲取的資料,從各種細胞群中快速識別癌細胞和幹細胞等稀有細胞。此外,賽默飛世爾科技於2022年3月推出了一款新型大容量電穿孔系統,旨在促進細胞療法的開發。預計這些創新將在未來幾年提振細胞分析市場的需求。
The global cell analysis market size reached USD 22.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 41.2 Billion by 2033, exhibiting a growth rate (CAGR) of 7.1% during 2025-2033. The shift towards personalized medicine, increasing cases of cancer across the globe, and growing integration of artificial intelligence and machine learning in cell analysis are some of the key factors, catalyzing the growth of the market.
Growing Burden of Cancer
The rising number of cancer cases across the world is primarily driving the market growth. Cell analysis tools and techniques in cancer research enable precise characterization of tumor cells, including their genetic mutations, protein expression profiles, and cellular interactions within the tumor microenvironment. The growing number of cancer patients is catalyzing the cell analysis market share. For instance, as per an American Cancer Society 2022 update, around 1,918,030 new cancer cases were estimated in the U.S. in 2022. Furthermore, lung cancer and breast cancer are two of the most common cancers found among individuals. The Canadian Cancer Society (CCS) stated that in 2020, nearly 29,800 Canadians were diagnosed with lung cancer, which accounted for 13% of all new cancer cases. About 21,200 Canadians were expected to die from lung cancer, which represented 25% of all cancer deaths in 2020. This indicates an inflating need for effective and more advanced cancer cell analysis. Thus, the increasing demand for effective and lasting cancer treatment is anticipated to offer lucrative growth opportunities to the overall market.
Increasing Development of Novel Molecules
The rising prevalence of various infectious diseases is prompting the development of novel molecules and vaccines, which in turn is augmenting the cell analysis market revenue. Cell analysis tools play a crucial role in drug discovery and development by enabling researchers to assess the efficacy, safety, and mechanism of action of potential drug candidates. Furthermore, various pharmaceutical and biotech firms are increasingly relying on cell analysis techniques and tools to introduce new and improved drugs. For instance, according to the data published by the Congressional Budget Office, in 2021, it was observed that pharmaceutical industries spent nearly USD 200 Billion on research and development in 2020 globally, compared to USD 83 Million in 2019. Similarly, Danaher Corporation invested USD 1,742 Million in its research and development in 2021, as compared to USD 1,348 Million in 2020. In addition, Bio-Rad Laboratories Inc., invested USD 879.6 Million in 2021 as compared to USD 800.3 Million in 2020. Thus, the rising investment in research and development by the companies further increases the capabilities of the company to adopt innovative cell analysis techniques, thereby propelling the cell analysis market growth.
Rising Number of Strategic Collaborations and Acquisitions
Various key market players are forming partnerships and collaborations to develop new and improved cell analysis methods, tools, and techniques. For instance, in August 2022, DeNovix Inc., the manufacturer of the award-winning CellDrop Automated Cell Counter, developed two dedicated nuclei counting apps capable of differentiating isolated nuclei and intact cells from debris. The CellDrop Series is a line of image-based, automated cell counters. Systems include a high-definition 7-inch touchscreen for live preview and instant review of results. Similarly, in November 2022, Sony Corporation launched the SFA - Life Sciences Cloud Platform, a flow cytometry data analysis cloud solution that can quickly identify rare cells, such as cancer cells and stem cells, from a wide variety of cell populations, using data obtained from flow cytometers. In addition to this, in March 2022, Thermo Fisher Scientific introduced a new large-volume electroporation system that is intended to enable the development of cell therapies. Such innovations are expected to bolster the cell analysis market demand in the coming years.
Flow cytometry products exhibit a clear dominance in the market
The cell analysis market report has provided a detailed breakup and analysis of the market based on the product. This includes flow cytometry products, qPCR Products, cell microarrays, microscopes, spectrophotometers, cell counters, HCS systems, and others. According to the report, flow cytometry products exhibit a clear dominance in the market.
Flow cytometry products are pivotal in the cell analysis market, offering precise quantification and characterization of cells based on their physical and chemical properties. Key components include flow cytometers, which analyze cells in fluid suspension using lasers to detect fluorescently labeled cells. Reagents such as fluorescent dyes and antibodies enable specific labeling for biomarker detection, while software facilitates data analysis and visualization. These products are essential in research, clinical diagnostics, and drug discovery, providing insights into cell function, differentiation, and disease mechanisms. Ongoing advancements in technology are enhancing sensitivity, multiplexing capabilities, and automation, expanding the utility of flow cytometry in diverse biomedical applications.
Cell identification analysis type holds the majority of the total market share
The cell analysis market research report has provided a detailed breakup and analysis of the market based on the analysis type. This includes cell identification, cell viability, cell signaling pathways/signal transduction, cell proliferation, cell counting and quality control, cell interaction, target identification and validation, single-cell analysis, and others. According to the report, cell identification analysis type holds the majority of the total market share.
Cell identification in cell analysis involves various techniques to distinguish and classify cells based on their morphological, molecular, or functional characteristics. Methods include microscopy for visual inspection, flow cytometry for quantitative analysis of cell surface markers, and molecular techniques like PCR for genetic profiling. Immunohistochemistry and immunofluorescence enable detection of specific proteins within tissues or cell samples. Advances in single-cell analysis technologies allow for high-resolution characterization of individual cells within heterogeneous populations. Accurate cell identification is crucial in understanding disease mechanisms, assessing treatment responses, and advancing personalized medicine by tailoring therapies based on individual cell profiles.
Molecular approaches represent the largest market share
Molecular approaches in cell analysis focus on studying cellular components at the molecular level to understand biological processes and diseases. Techniques include PCR (Polymerase Chain Reaction) for amplifying and detecting DNA or RNA sequences, Western blotting for protein detection and quantification, and next-generation sequencing (NGS) for comprehensive genomic analysis. These methods enable researchers to investigate gene expression, mutations, protein interactions, and epigenetic modifications within cells. Molecular approaches are vital in biomarker discovery, drug development, and personalized medicine, offering insights into cellular function and disease mechanisms with high sensitivity and specificity. Continued advancements enhance their utility in diverse biomedical research applications.
Pharmaceutical and biotechnology companies and CROs currently account for the majority of the total market share
Pharmaceutical and biotechnology companies develop and commercialize drugs and therapies for medical use. They conduct extensive research and clinical trials to discover new compounds, validate their efficacy and safety, and obtain regulatory approvals. Contract Research Organizations (CROs) support these efforts by providing specialized, such as clinical trial management, data analysis, and regulatory compliance. CROs enable companies to outsource non-core activities, accelerate timelines, and manage costs effectively. Furthermore, the increasing rate of new drug development is also contributing to the segment's growth. For instance, between 2010 and 2019, around 38 new drugs were approved each year, on an average. That is about a 60% increase compared with the previous decade. Drug approvals reached a new peak in 2018, surpassing the record number of approvals of the late 1990s. The cell analysis market statistics by IMARC indicate that together, pharmaceutical/biotech firms and CROs are playing crucial roles in advancing healthcare innovation, bringing new treatments to market, and improving patient outcomes through rigorous scientific research and development.
North America currently dominates the global market
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America currently dominates the global market.
The growth of the region can be attributed to the increase in incidences of cancer and rising corporate and government funding in cell-based research. For instance, according to the Canadian Cancer Statistics 2022 Special Report, the number of people living with and after cancer in Canada continued to grow to over 1.5 million people. Additionally, according to another report, 2 in 5 Canadians are expected to be diagnosed with cancer in their lifetime. Approximately 1 in 4 Canadians is expected to die of the disease. Besides this, the presence of major companies, the growing number of product launches, and the strong R&D in biotechnology are further positively impacting the cell analysis market outlook. For instance, in September 2022, Becton, Dickinson, and Company launched BD Research Cloud, a cloud-based software solution designed to streamline the flow cytometry workflow to enable higher-quality experiments with faster time to insight for scientists working across a range of disciplines, including immunology, virology, oncology, and infectious disease monitoring.